Drugs / Bisoprolol
Bisoprolol
also known as
Concor · Bisoprolol Fumarate · Bipranix · Bisoprolol fumarate component of ziac · Bisoprolol hemifumarate · Cardicor · CL 297,939 · Congescor · +15 more
Other / unclassified targets ADRB1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ZEBETA | — | 1992-07-31 | fda.gov ↗ |
Trials 57
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04356196 | Jun → Dec 2021 | — | Assiut University | Unknown | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT06831864 | Feb → May 2025 | symptomatic heart failure | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01925300 | Jul → Sep 2013 | — | HK inno.N Corporation | Withdrawn | No outcome recorded |
| Phase 1 | NCT01284868 | Jul → Nov 2009 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT02256722 | Oct → Nov 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03361280 | Feb 2015 → Mar 2016 | chronic kidney disease | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 1/2 | NCT01246037 | Feb 2011 → Jan 2014 | idiopathic pulmonary arterial hypertension | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
| Phase 1/2 | NCT01016886 | Sep 2010 → Sep 2015 | breast cancer, heart failure | University of Alberta | Unknown | No outcome recorded |
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT05536284 | Sep 2021 → May 2022 | acute coronary syndrome | Damanhour University | Completed | No outcome recorded |
| Phase 2 | NCT05536271 | Sep 2021 → Jun 2022 | acute coronary syndrome | Damanhour University | Completed | No outcome recorded |
| Phase 2 | NCT03640312 | Aug 2019 → May 2022 | hypertensive disorder | Washington University School of Medicine | Completed | Missed primary |
| Phase 2 | NCT00702156 | Mar 2005 → Feb 2008 | chronic obstructive pulmonary disease, heart failure | NHS Greater Glasgow and Clyde | Terminated | Missed primary Stop: Enrollment |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03779646 | Jan 2019 → Jul 2023 | Duchenne muscular dystrophy, dilated cardiomyopathy | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 39 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT07569640 | Aug 2026 → Apr 2029 expected | symptomatic heart failure | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 3 | NCT06276127 | Apr 2025 → Apr 2027 expected | atrial fibrillation, atrial flutter | Oman Medical Speciality Board | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05540600 | Sep 2022 → Jan 2023 | atrial fibrillation | University of Monastir | Unknown | Missed primary |
| Phase 3 | NCT05175066 | Nov 2020 → Oct 2021 | cardiomyopathy, chemotherapy-induced toxicity, diastolic heart failure, systolic heart failure | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03485482 | Mar 2018 | cardiovascular disorder | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT04704947 | Oct 2017 → Oct 2030 expected | poisoning | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT02236806 | Jul 2015 → Jun 2022 | breast cancer, chemotherapy-induced toxicity | Careggi University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01977794 | Mar 2014 → Mar 2015 | essential hypertension | Merck KGaA, Darmstadt, Germany | Completed | Met primary |
| Phase 3 | NCT00323973 | Jul 2003 → Jul 2005 | Chagas cardiomyopathy, heart failure | Fundación Cardiovascular de Colombia | Completed | No outcome recorded |
| Phase 428 trials · 3 met primary · 3 missed | ||||||
| Phase 4 | NCT04432610 | Jan → Dec 2030 | — | Clinical Hospital Center Zemun | Withdrawn | No outcome recorded |
| Phase 4 | NCT05880056 | Aug 2024 → Apr 2025 overdue | essential hypertension | Genuine Research Center, Egypt | Recruiting | No outcome recorded |
| Phase 4 | NCT06035978 | Mar 2024 → Apr 2026 | symptomatic heart failure | University Hospital Ostrava | Unknown | No outcome recorded |
| Phase 4 | NCT05585125 | Feb 2024 → Jul 2026 overdue | diastolic heart failure | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05019027 | Jan 2024 → Mar 2026 overdue | amyloidosis, heart disorder | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05637853 | Oct 2022 → Aug 2024 overdue | symptomatic heart failure | Göteborg University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05294887 | Mar 2022 → Jun 2024 | Prinzmetal angina, coronary microvascular disorder, nonobstructive coronary artery disease | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 4 | NCT04769362 | May 2021 → Jan 2026 overdue | myocardial infarction | Samsung Medical Center | Recruiting | Met primary |
| Phase 4 | NCT04085562 | Sep 2019 → Feb 2021 | renal hypertension | Alexandria University | Completed | Met primary |
| Phase 4 | NCT03778554 | Dec 2018 → Apr 2025 overdue | ST-elevation myocardial infarction | Bispebjerg Hospital | Active not recruiting | Met primary |
| Phase 4 | NCT03596385 | Oct 2018 → Jan 2025 | myocardial infarction | National Center for Cardiovascular Research Carlos III | Completed | Missed primary |
| Phase 4 | NCT03278509 | Sep 2017 → Nov 2023 | ST-elevation myocardial infarction | Karolinska Institutet | Unknown | Missed primary |
| Phase 4 | NCT03026088 | Mar 2017 → Dec 2018 | heart failure | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02380053 | Jun 2016 → Apr 2019 | chronic obstructive pulmonary disease | University of Dundee | Completed | No outcome recorded |
| Phase 4 | NCT02817360 | Feb 2016 → Dec 2025 overdue | heart disorder, type 2 diabetes mellitus | Martin Huelsmann | Recruiting | No outcome recorded |
| Phase 4 | NCT01868880 | Feb 2016 → Dec 2023 | — | Policlinico Casilino ASL RMB | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02539810 | Sep 2015 → Dec 2016 | renal artery atheroma, resistant hypertension | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 4 | NCT02398929 | Jan 2013 → Jan 2021 | essential hypertension | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT01939509 | Feb 2012 → Oct 2014 | hypertensive disorder, metabolic syndrome X | Hospital Italiano de Buenos Aires | Completed | No outcome recorded |
| Phase 4 | NCT01508325 | Dec 2011 → Apr 2014 | essential hypertension | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT01762436 | Nov 2010 → Feb 2012 | essential hypertension | Ruijin Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01243827 | Nov 2010 → Dec 2012 | hypertensive disorder | Yoshio Matsui | Unknown | No outcome recorded |
| Phase 4 | NCT01251146 | Nov 2010 → Feb 2012 | essential hypertension | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT01066039 | Apr 2010 → Apr 2013 | hypertensive disorder, type 2 diabetes mellitus | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT01190436 | Dec 2009 → Dec 2011 | hypertensive disorder | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT01079962 | Dec 2009 → Oct 2011 | hypertensive disorder | Merck KGaA, Darmstadt, Germany | Completed | Missed primary |
| Phase 4 | NCT01074307 | Oct 2009 → Aug 2012 | congestive heart failure | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT01104558 | Dec 2008 → Jul 2010 | heart failure | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT07123506 | Sep 2025 → Nov 2028 expected | atrial fibrillation, atrial flutter, atrial septal defect | Yonsei University | Not yet recruiting | No outcome recorded |
| — | NCT07029906 | Apr 2025 → Dec 2027 expected | heart failure | Imperial College London | Recruiting | No outcome recorded |
| — | NCT04823442 | Jan 2021 → Apr 2022 | type 2 diabetes mellitus | University of Sherbrooke | Completed | No outcome recorded |
| — | NCT04513509 | Oct 2020 → Jun 2022 | atrial fibrillation | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT04221919 | Jan 2020 → Jan 2021 | strictly posterior acute myocardial infarction | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| — | NCT01273298 | Jun 2008 → Sep 2010 | chronic obstructive pulmonary disease | Laval University | Completed | No outcome recorded |
| — | NCT00382421 | Feb 1992 → Apr 2006 | myocardial ischemia | Luzerner Kantonsspital | Completed | No outcome recorded |
| Comparator or background therapy55 trials | ||||||
| Phase 0 | NCT06643221 Comparator | Jan 2018 → May 2031 expected | leukemia, lymphoma | University of Arizona | Recruiting | No outcome recorded |
| Phase 0 | NCT01955759 Background | Dec 2013 → Dec 2014 | — | Heart Center BH Tuzla | Unknown | No outcome recorded |
| Phase 0 | NCT02106286 Comparator | Feb 2011 → Dec 2013 | abdominal aortic aneurysm | Michelle Mossa | Completed | No outcome recorded |
| Phase 2 | NCT05430048 Comparator | Jul → Oct 2022 | hemorrhagic disease | Zagazig University | Completed | No outcome recorded |
| Phase 2 | NCT04588935 Comparator | Jul 2019 → Feb 2023 | female breast carcinoma | State Institution "Republican Scientific and Practical Center" Cardiology, Belarus | Completed | No outcome recorded |
| Phase 2 | NCT04320589 Comparator | Jun 2019 → Aug 2021 | pheochromocytoma | National Cancer Institute, Egypt | Completed | No outcome recorded |
| Phase 2/3 | NCT00562952 Comparator | Nov 2007 → Dec 2011 | coronary artery disorder, diabetes mellitus, heart failure | Medical University of Vienna | Completed | No outcome recorded |
| Phase 3 | NCT03917914 Comparator | Jun 2020 → Mar 2025 | cardiovascular disorder, chronic obstructive pulmonary disease | The George Institute | Completed | No outcome recorded |
| Phase 3 | NCT05288400 Comparator | May → Dec 2018 | essential hypertension | Servier | Completed | No outcome recorded |
| Phase 4 | NCT07513883 Background | Mar 2026 → Sep 2028 expected | heart failure | Ziekenhuis Oost-Limburg | Recruiting | No outcome recorded |
| Phase 4 | NCT07103655 Background | Mar → Nov 2026 expected | hypertrophic cardiomyopathy | Second Affiliated Hospital, Zhejiang University, School of Medicine | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07298993 Comparator | Feb 2026 → Apr 2029 expected | heart failure | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07238452 Comparator | Dec 2025 → Dec 2032 expected | atrial fibrillation, symptomatic heart failure | University of British Columbia | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06562582 Comparator | Jan 2025 → Dec 2027 expected | myocardial infarction | Vastra Gotaland Region | Recruiting | No outcome recorded |
| Phase 4 | NCT07327749 Comparator | Oct 2022 → Dec 2024 | hypertensive disorder | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT05569382 Comparator | Aug 2022 → Apr 2027 expected | hypertrophic cardiomyopathy | Morten Steen Kvistholm Jensen | Recruiting | No outcome recorded |
| Phase 4 | NCT05730413 Comparator | Aug 2021 → Sep 2023 | atrial fibrillation, coronary artery disorder | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT05122780 Background | Jul 2021 → Jul 2025 overdue | myocardial infarction | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04767061 Comparator | Apr 2021 → Apr 2022 | diastolic heart failure | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT04757584 Comparator | Apr 2021 → Apr 2023 | diastolic heart failure | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT04575675 Background | May → Nov 2020 | heart failure, hypotensive disorder | Cheng-Hsin General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03646357 Comparator | Oct 2018 → Apr 2025 overdue | ST-elevation myocardial infarction | Oslo University Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03800264 Comparator | May → Nov 2018 | atrial fibrillation | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT07405229 Comparator | May 2018 → Dec 2032 expected | cardiac arrest, ventricular fibrillation | Bo Gregers Winkel | Recruiting | No outcome recorded |
| Phase 4 | NCT02391337 Comparator | Dec 2016 → Apr 2019 | atrial fibrillation | University of Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT02832973 Comparator | Sep 2015 → Dec 2017 | resistant hypertension | Sao Jose do Rio Preto Medical School | Completed | No outcome recorded |
| Phase 4 | NCT03850093 Comparator | Aug 2015 → Oct 2016 | hypertensive disorder | Zagazig University | Completed | No outcome recorded |
| Phase 4 | NCT02200822 Comparator | Jul 2014 → Feb 2019 | heart failure | Hasselt University | Completed | No outcome recorded |
| Phase 4 | NCT02171988 Comparator | Mar 2014 → Feb 2016 | postural orthostatic tachycardia syndrome | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01162902 Comparator | Sep 2013 → Jan 2015 | coronary artery disorder | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03011775 Background | Nov 2012 → Jun 2014 | coronary atherosclerosis, metabolic syndrome X | Ukrainian Medical Stomatological Academy | Completed | No outcome recorded |
| Phase 4 | NCT01656005 Comparator | Aug 2012 → Jul 2016 | chronic obstructive pulmonary disease | University of Dundee | Completed | No outcome recorded |
| Phase 4 | NCT01579058 Comparator | Jul 2012 → May 2014 | aortic valve stenosis | Asan Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT01030458 Comparator | Sep 2010 → Mar 2012 | hypertensive disorder | KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT02369081 Comparator | May 2009 → Jul 2015 | resistant hypertension | University of Cambridge | Unknown | No outcome recorded |
| Phase 4 | NCT00517725 Comparator | Jul 2007 → May 2010 | congestive heart failure | Centro Cardiologico Monzino | Completed | No outcome recorded |
| Phase 4 | NCT00391846 Background | Oct 2006 → Jan 2009 | left ventricular failure | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT03276598 Comparator | Nov 1999 → Apr 2004 | essential hypertension | Helsinki University Central Hospital | Completed | No outcome recorded |
| — | NCT07445334 Comparator | Mar 2026 → Sep 2027 expected | ventricular tachycardia | Western Sydney Local Health District | Recruiting | No outcome recorded |
| — | NCT07568574 Background | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
| — | NCT07335900 Background | Dec 2025 → Dec 2026 expected | aortic valve stenosis | RenJi Hospital | Recruiting | No outcome recorded |
| — | NCT07491718 Comparator | Aug 2025 → Aug 2028 expected | Tako-tsubo cardiomyopathy | University of Edinburgh | Recruiting | No outcome recorded |
| — | NCT06930092 Comparator | Aug 2025 → Apr 2028 expected | cardiomyopathy | Seoul National University Hospital | Recruiting | No outcome recorded |
| — | NCT07045038 Background | Jul 2025 → Apr 2026 | moderate heart failure | Cairo University | Completed | No outcome recorded |
| — | NCT06699342 Comparator | Jan 2025 → Dec 2027 expected | atrial fibrillation | Seoul National University Hospital | Recruiting | No outcome recorded |
| — | NCT06657404 Background | Oct → Dec 2024 overdue | atrial fibrillation | Yumei Xue | Recruiting | No outcome recorded |
| — | NCT03701880 Background | Sep 2018 → Dec 2019 | heart failure | Ain Shams University | Unknown | No outcome recorded |
| — | NCT02364089 Comparator | Apr 2015 → Mar 2022 | adrenal gland disorder | University Hospital, Bordeaux | Completed | No outcome recorded |
| — | NCT02355821 Comparator | Apr 2015 → Jun 2018 | hypertensive disorder, osteoporosis | National Research Center for Preventive Medicine | Completed | No outcome recorded |
| — | NCT02086019 Background | May 2014 → Sep 2019 | acute coronary syndrome | Brighton and Sussex University Hospitals NHS Trust | Completed | No outcome recorded |
| — | NCT02137733 Comparator | Jun 2013 → May 2016 | heart failure | Mebix Inc | Unknown | No outcome recorded |
| — | NCT00882856 Comparator | Apr 2009 → Dec 2016 | — | University of Aarhus | Completed | No outcome recorded |
| — | NCT00878384 Comparator | Apr 2009 → Jun 2012 | atrial fibrillation, heart failure | Royal Brompton & Harefield NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT00292162 Comparator | Jan 2007 → Jul 2009 | atrial fibrillation, heart failure | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-01-08 | Astellas Pharma Inc | Regulatory Additional Approvals for Bisono® Tape, a Transdermal Patch containing a β1 Blocker, for Atrial Fibrillation, for a 2 mg strength and for improved formulations of 4 mg and 8 mg strengths in Japan astellas.com ↗
Toa Eiyo received approvals for Bisono® Tape 2 mg, Bisono® Tape 4 mg and Bisono® Tape 8 mg (collectively, “Bisono® Tape”, non-proprietary name: bisoprolol), transdermal patches containing a β1 blocker, in Japan for the new indication of atrial fibrillation. |
| 2013-06-28 | Astellas Pharma Inc | Regulatory Approval in Japan for Bisono®Tape, Transdermal Patch of β1 Blocker for The First Time in The World astellas.com ↗
Toa Eiyo has obtained the marketing approval for Bisono® Tape 4mg and Bisono® Tape 8mg |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-07-26 | Zydus Lifesciences Limited | Zydus receives final approval from the USFDA for Bisoprolol Fumarate Tablets zyduslife.com ↗ |
| 2019-01-08 | Astellas Pharma Inc | Additional Approvals for Bisono® Tape, a Transdermal Patch containing a β1 Blocker, for Atrial Fibrillation, for a 2 mg strength and for improved formulations of 4 mg and 8 mg strengths in Japan astellas.com ↗ |
| 2013-06-28 | Astellas Pharma Inc | Approval in Japan for Bisono®Tape, Transdermal Patch of β1 Blocker for The First Time in The World astellas.com ↗ |
Evidence & citations 28 cited values
Every value below carries the sentence it was read from. 113 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bisoprolol | “Pharmacologic therapy includes rate control with beta-blockers (e.g., bisoprolol), calcium channel blockers (e.g., diltiazem), or antiarrhythmic drugs (e.g., flecainide,...” NCT06699342 ↗109“HFrEF polypill strength 1: bisoprolol 2.5 mg + losartan 25 mg + eplerenone 25 mg + dapagliflozin 10 mg; HFrEF polypill strength 2: bisoprolol 5 mg + losartan 50 mg + eplerenone...” NCT06831864 ↗ “Randomisation will be stratified according to the type of AMI (ie, ST-segment-elevation MI or non-ST-segment-elevation MI), type of β-blocker (carvedilol, bisoprolol, nebivolol...” PMID 39645270 ↗ Aug 2024 “Other names: acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol,...” NCT05585125 ↗ “The study intervention is a HFrEF polypill consisting of bisoprolol (beta-blocker), losartan (ARB), eplerenone (MRA), and dapagliflozin (SGLT2i) manufactured using the...” NCT07569640 ↗ “Other Names: * acebutolol * atenolol * betaxolol * bisoprolol * carvedilol * labetalol * metoprolol succinate * metoprolol tartrate * nadolol * nebivolol * penbutolol *...” NCT05019027 ↗ “A non-selective betablocker: Propranolol Retard 80 mg daily or Nadolol 40 mg daily OR 2) A selective betablocker: Atenolol 25 mg daily, Bisoprolol 2.5 mg daily or Metoprolol 50 mg.” NCT07405229 ↗ “All patients will be started on an SGLT2i (Empagliflozin or Dapagliflozin) and a betablocker (Metoprolol, Bisoprolol or Carvedilol) right after study inclusion.” NCT05637853 ↗ “Participants received either a quadpill of candesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg or candesartan 8 mg for 12 weeks.” PMID 38584159 ↗ Apr 2024 “If sotalol is contraindicated, an alternative BB may be initiated using standard doses (metoprolol, atenolol, bisoprolol).” NCT07445334 ↗ “The beta-blocker agent may include atenolol, bisoprolol, carvedilol, metoprolol succinate, or metoprolol tartrate.” NCT07298993 ↗ |
| Known as | Bipranix | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | Bisoprolol Fumarate | “Subjects will receive bisoprolol fumarate (Concor®) at a dose of 5 milligram (mg) once daily orally as sustained release (SR) tablets for a period of 4 weeks.” NCT01508325 ↗ |
| Known as | Bisoprolol fumarate component of ziac | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | Bisoprolol hemifumarate | “Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab” NCT01925300 ↗ |
| Known as | Cardicor | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | CL 297,939 | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | Concor | “Bisoprolol (Concor) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.” NCT06035978 ↗5“All patients will enroll to maximum doses guideline medical treatment that include (Beta blockers-Aspocid- Ator-Concor-Tritace).” NCT07045038 ↗ “patients will receive Oral bisoprolol 2.5 mg (Concor 2.5 mg; Merck/Amoun) 90 min preoperative.” NCT05430048 ↗ “Concor (bisoprolol fumarate) 5mg, 1 tablet/day” NCT05288400 ↗ “Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab” NCT01925300 ↗ “Bisoprolol (Concor): 2.5-20 mg/day” NCT04320589 ↗ |
| Known as | Congescor | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | Detensiel | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | Emconcor | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | Emcor | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | Emcor ls | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | EMD 33 512 | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | Euradal | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | Isoten | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | Isoten mitis | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | Monocor | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | Nerkardou | “One ODF of bisoprolol 5 mg (Nerkardou 5 mg) Dosage form description: Bisoprolol oral dissolved film ODF: equivalent to 5 mg of bisoprolol fumarate.” NCT05880056 ↗ |
| Known as | Soloc | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | Soprol | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | Speridol | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | Vivacor | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Known as | Zebeta | ChEMBL registry synonym — accepted as the source's own label CHEMBL645 ↗ |
| Action | Inhibit | “Bisoprolol is a beta-1 selective blocker with the highest selectivity for this receptor” NCT00323973 ↗1“Beta-1 adrenergic receptor antagonist” CHEMBL645 ↗ |
| Modality | Other / unclassified | “Carvedilol and bisoprolol are established beta-blockers for treating hypertension or chronic heart failure” NCT01243827 ↗ |
| Route | Oral | “lowest oral dose” NCT00323973 ↗ |
| Target | ADRB1 | “Beta-1 adrenergic receptor antagonist” CHEMBL645 ↗ |